Intermittent treatment with azithromycin and ethambutol for non-cavitary Mycobacterium avium complex pulmonary disease.
We evaluated the efficacy of intermittent azithromycin and ethambutol therapy for non-cavitary Mycobacterium avium complex pulmonary disease (MAC-PD). Twenty-nine of 38 patients (76%) achieved sputum culture conversion after 12 months of treatment, and sputum smear positivity was an independent factor for failure to achieve culture conversion (adjusted odds ratio: 26.7; 95% confidence interval: 2.1-339.9; p = 0.011). Intermittent azithromycin and ethambutol could be an optional treatment regimen for non-cavitary MAC-PD.